The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis

European Psychiatry

Volumn 27, Issue 4, 2012, Pages 275-280

  Faber, G ^a   Smid, H G O M ^b   Van Gool, A R ^a   Wiersma, D ^b   Van Den Bosch, R J ^b  

^a Yulius Mental Health Institute   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antipsychotics; Guided discontinuation; Neurocognitive function; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; BRIEF PSYCHOTIC DISORDER; COGNITION; DELUSIONAL DISORDER; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GUIDED DISCONTINUATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT WITHDRAWAL; VERBAL MEMORY; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 79955421062     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.02.003     Document Type: Article

References (32)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Am J Psychiatry 2004;161(Suppl. 2).
2. Barker M.J., Greenwood K.M., Jackson M., Crow S.F. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 2004, 19:437-454.
3. de Bruijn E.R.A., Sabbe B.G.C., Hulstijn W., Ruigt G.S.F., Verkes R.J. Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers. Brain Res 2006, 1105:122-129.
4. Carpenter W.T., Gold J.M. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 2003, 52:969-971.
5. Conway Greig T., Nicholls S.S., Wexler B.E., Bell M.D. Test-retest stability of neuropsychological testing and individual differences in variability in schizophrenia outpatients. Psychiatry Res 2004, 129:241-247.
6. Davidson M., Galderisi S., Weise M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-682.
7. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
8. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the " right stuff" ?. Schizophr Bull 2000, 26:119-136.
9. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004, 72:41-51.
10. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia. Is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122.
11. Harvey P.D., Keefe R.S.E. Studies in cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001, 158:176-184.
12. Harvey P.D., Palmer B.W., Heaton R.K., Mohamed S., Kennedy J., Brickman A. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 2005, 162:110-117.
13. Harvey P.D., Rabinowitz J., Eerdekens M., Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005, 162:1888-1895.
14. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
15. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull 1987, 13:261-276.
16. Keefe R.S.E., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., et al. Comparative effect of atypical and conventional drugs on neurocognition in first-episode psychosis: a randomised, double-blind trial of olanzapine versus low dose of haloperidol. Am J Psychiatry 2004, 161:985-995.
17. Keefe R.S.E., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., et al. Long-term neurocognitive effects of olanzapine or low dose of haloperidol in first-episode psychosis. Biol Psychiatry 2006, 59:97-105.
18. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007, 64:633-647.
19. Lezak M. Neuropsychological assessment 1995, Oxford University Press, New York, NY. 3rd ed.
20. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004, 161:116-124.
21. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004, 72:29-39.
22. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008, 165:203-213.
23. O'Carroll R.E., Smith K., Couston M., Cossar J.A., Hayes P.C. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res 2009, 9:121-124.
24. Potkin S.G., Fleming K., Jin Y., Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001, 21:479-483.
25. Rodriguez-Sanchez J.M., Crespo-Facorro B., Gonzalez-Blanch C., Perez-Iglesias R., Vazquez-Barquero J.L. Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. Br J Psychiatry 2007, 191(Suppl. 51):107-110.
26. SPSS 15.0 for Windows. SPSS Inc., Chicago Ill; 2006.
27. Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. Administration and scoring manual 1997, Psychological Corporation/Harcourt Brace, San Antonio, Texas. 3rd ed.
28. Weickert T.W., Goldberg T.E., Marenco S., Bigelow L.B., Egan M.F., Weinberger D.R. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003, 28:1491-1500.
29. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
30. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89:211-224.
31. World Health Organisation. Schedules for Clinical Assessment in Neuropsychiatry; 1992. WHO. Dutch version; 1999.
32. Wunderink L., Nienhuis F.J., Sytema S., Slooff C.J., Knegtering H., Wiersma D. Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007, 68:654-661.